|
|
|
|
| LEADER |
04287nam a2200409 u 4500 |
| 001 |
EB001853612 |
| 003 |
EBX01000000000000001017915 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
181108 r ||| eng |
| 020 |
|
|
|a 0309468051
|
| 020 |
|
|
|a 9780309468053
|
| 050 |
|
4 |
|a HD9665.4
|
| 100 |
1 |
|
|a Augustine, Norman R.
|e [editor]
|
| 245 |
0 |
0 |
|a Making medicines affordable
|h Elektronische Ressource
|b a national imperative
|c Norman R. Augustine, Guru Madhavan, and Sharyl J. Nass, editors ; Committee on Ensuring Patient Access to Affordable Drug Therapies, Board on Health Care Services, Health and Medicine Division ; a consensus study report of the National Academies of Sciences, Engineering, Medicine
|
| 260 |
|
|
|a Washington, D.C.
|b National Academies Press
|c 2017, [2017]©2017
|
| 300 |
|
|
|a 1 PDF file (xxviii, 206 pages)
|b color illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references (pages 125-150)
|
| 505 |
0 |
|
|a The affordability conundrum -- Complexity in action -- Factors influencing affordability -- Strategies to improve affordability and availability -- References -- Appendices. A Dissenting View: Michael Rosenblatt and Henri Termeer -- A Minority Perspective: Rena Conti, Stacie Dusetzina, Martha Gaines,Rebekah Gee, Victoria Hale, Peter Sands, and Alan Weil
|
| 653 |
|
|
|a United States
|
| 653 |
|
|
|a Health Policy
|
| 653 |
|
|
|a Health Services Accessibility / economics
|
| 653 |
|
|
|a Pharmaceutical Preparations / economics
|
| 653 |
|
|
|a Drug Costs
|
| 700 |
1 |
|
|a Madhavan, Guruprasad
|e [editor]
|
| 700 |
1 |
|
|a Nass, Sharyl J.
|e [editor]
|
| 710 |
2 |
|
|a National Academies of Sciences, Engineering, and Medicine (U.S.)
|b Committee on Ensuring Patient Access to Affordable Drug Therapies
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Consensus study report
|
| 028 |
5 |
0 |
|a 10.17226/24946
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK493094
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care
|
| 520 |
|
|
|a Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugs--coupled with the broader trends in overall health care costs--is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design.
|
| 520 |
|
|
|a Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicines--and health care at large--more affordable for everyone has become a socioeconomic imperative.
|